Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
iptacopan - CFB inhibitor
Financial review
Immunology
2023 priorities
Innovation: Clinical trials
Neuroscience
NCT04578834 APPLAUSE-IgAN (CLNP023A2301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Readout
Milestone(s)
Publication
IgA nephropathy
Phase 3
450
Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine
collection) at 9 months
Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated
over 24 months
Arm 1 - LNP023 200mg BID
Arm 2 - Placebo BID
Primary IgA Nephropathy patients
2023 (primary endpoint for US initial submission, 9 months UPCR)
2025 (24 months)
Perkovic et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1:
Study Design
Wong et al. 2021, Nephrology Dialysis Transplantation, Vol. 36, Suppl. 1:
IPTACOPAN (LNP023): A NOVEL ORAL COMPLEMENT
ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY AND
EFFECTIVELY STABILISES EGFR IN C3 GLOMERULOPATHY
61 Investor Relations | Q4 2022 Results
Oncology
Appendix
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation